Objectives: To initially clarify the efficacy and tolerability of nintedanib in patients with
idiopathic-inflammatory-myopathy-related interstitial lung disease (IIM-ILD). Methods: A …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) is a severe and fatal
manifestation of systemic autoimmune disorders. Therapies rely on immunomodulators but …

Introduction Nintedanib can inhibit processes involved in the progression of fibrosis and can
reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) …

Objective To analyze the efficacy and safety of nintedanib in patients with fibrosing
autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype …

Background: In the INBUILD trial in patients with progressive fibrosing ILDs, nintedanib
reduced the rate of decline in forced vital capacity (FVC) versus placebo over 52 weeks both …

Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases
(ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with …

Background The primary analysis of the INBUILD trial showed that in subjects with
progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in …

Nintedanib (Ofev™), an oral triple kinase inhibitor targeting pro-fibrotic pathways, has been
used for treatment of idiopathic pulmonary fibrosis (IPF). Based on positive results from …

Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The
antifibrotic agents may prevent disease progression of these diseases. Nintedanib is a triple …